Recruiting
Investigational
Study of PF-07275315 versus placebo for efficacy and safety in adults with moderate-to-severe chronic obstructive pulmonary disease (COPD)
Investigational
- Participants:Adults
PF-07275315
- 1 / 1
- trials open to patients / all trials
- 9+
- Countries
About the substance
What is PF-07275315?
PF-07275315 is a protein-based investigational substance being developed for adults with moderate-to-severe chronic obstructive pulmonary disease (COPD).[1] It is supplied by Pfizer Inc. and has no marketing authorisation in the product records, meaning it is not yet an approved medicine.[1] The substance appears as the test product in one registered clinical trial.[1]
How does PF-07275315 work?
The registry records do not describe the molecular target or mechanism of action of PF-07275315. It is classified in the therapeutic area of respiratory tract diseases.[1] The trial is designed to assess whether the substance can improve lung function and reduce COPD flare-ups compared with placebo.[1]
Which conditions is PF-07275315 studied for?
- Moderate-to-severe chronic obstructive pulmonary disease (COPD) — a long-term breathing difficulty. The trial studies PF-07275315 in adults with this condition.[1]
How is PF-07275315 given?
PF-07275315 is prepared as a solution for injection and given by subcutaneous injection, which means it is injected under the skin.[1] The registry record does not report the dose, because the dose is listed as 0 mg, meaning the dose was not reported.[1]
What do the clinical trials show?
One trial is registered for PF-07275315: EU CT number 2024-518587-12-00, currently authorised.[1] It is a Phase 2/3 interventional study planning to enrol 1,056 participants with moderate-to-severe COPD.[1] The Phase 2 part assesses two doses of PF-07275315 compared with placebo, while the Phase 3 part assesses efficacy compared with placebo.[1]
The primary outcomes differ by phase. In Phase 2, the main measure is the change from baseline in pre-bronchodilator forced expiratory volume in one second (FEV1) at Week 24 compared with placebo; FEV1 is how much air a person can force out in one second.[1] In Phase 3, the main measure is the annualised rate of moderate or severe COPD exacerbations (ECOPD), meaning how many flare-ups occur per year.[1]
What side effects are known?
No side effect information is available in the registry data or supplementary sources for PF-07275315.
Conditions where PF-07275315 is being studied
Each condition opens its own overview and trial list
Trials with PF-07275315
Recruiting trials first
Quick filters